Curriculum vitae matthew ryan weir, M. D



Download 0.51 Mb.
Page4/7
Date conversion04.02.2017
Size0.51 Mb.
1   2   3   4   5   6   7
PUBLICATIONS - (NON-REFEREED)


  1. Thornton GF, Weir MR. Extrapulmonary tuberculosis: where and how to find it. Medi guide to Infectious Diseases 1983; 3(3):1-4.

  2. Weir MR. An elderly patient undergoing second renal transplantation. No. 3 in a series of case studies. Sandoz Pharmaceuticals 1986.

  3. Cohen S, Weir MR, Dagher FJ, Bentley FR, Revie DR, Ordonez J, Chretien P. Effect of cyclosporine on total lymphocyte and T-cell counts in renal-transplant recipients. New England Journal of Medicine 1986; 314:447-448 (letter).

  4. Weir MR. Hypertension therapy: avoiding end-organ damage. Urban Practice Today 1988; 2:3-5.

  5. Weir MR. The enigma of extrapulmonary tuberculosis (editorial). New York State J Med 1989; 89:251-252.

  6. Weir MR. (Moderator), Epstein M, Raij L, Dworkin LD, Hollenberg NH, Curtis JJ. "Perspectives in renal protection: where do ACE inhibitors and calcium channel blockers fit in?" as appearing in Perspectives in Hypertension and Renal Disease. 1989;2:1-34.

  7. Weir MR. Impact of blood pressure control on renal function. Current Concepts in Antihypertensive Therapy 1989; 1:56-63.

  8. Weir MR. Renal function and its implications for antihypertensive therapy. Practical Cardiology 1990; October: 43-47.

  9. Weir MR, Haynie R, Vertes V, Pinson R, Kong BW, Jenkins P, Lavin PT. A comparison of the efficacy and tolerability of enalapril and sustained-release diltiazem in mild to moderate essential hypertension. Clin Ther 1990; 12:473-481.

  10. Burris JF, Weir MR, Oparil S, Cady WJ. The effects of thiazides plus calcium channel blockers. JAMA 1990; 264:971-973. (letter)

  11. Weir MR. Strategies in treating hypertension: Physiology of pharmacologic intervention to prevent renal insufficiency. Advances in Cardiology 1990; 1:1-10.

  12. Weir MR, Li XW, Gomolka D, Peppler R, O'Bryan-Tear CG, Moran MA. Immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45662). Transplant Proc 1991; 23:1074-1077.

  13. Weir MR (Moderator), Sowers JR, Bauer JH, Rostand SG, Bakris GL. Perspectives in renal protection: high-risk hypertensive subpopulations. Perspectives in Hypertension and Renal Disease 1991; 4:1-28.

  14. Weir MR, Hise MK. Hypertension in blacks: pathophysiology and therapy. Hypertension: New approaches to drug therapy 1991; 3:2-16.

  15. Weir MR. Hypertension and arthritis: coprevalence and implications for therapy. Comorbidity in Cardiovascular Disease 1992; 1:3-9.

  16. DeQuattro V, Weir MR. Bisoprolol Fumerate/Hydrochlorothiazide 6.25 mg: a new, low-dose option for first-line antihypertensive therapy. Advances in Therapy 1993; 10:197-206.

  17. Weir MR. A new antihypertensive strategy to minimize dose-related side effects: low-dose multi mechanism therapy. Advances in Therapy 1993; 10:293-299.

  18. Weir MR. Value of adjunctive calcium channel blockers to broaden the therapeutic index of cyclosporine therapy. Transplantation and Immunology Newsletter 1994; 10:3,11-13.

  19. Weir MR. Hypertension - case and comment - multiple problems with multiple solutions. Patient Care 1995;29(11):169-170.

  20. Flack JM, Mensah GA, McVeigh GE, Weir MR, Reed JW. Diagnosis, evaluation, and management of hypertension in an ambulatory clinic setting. J of Clinical Outcomes Management 1995;2(5):39-66.

  21. Weir MR,. The role of dietary salt in altering the management of hypertension. International Society of Hypertension in Blacks 1995;7-8.

  22. Weir MR, Schroeder JS, eds. Primary prevention versus end-stage treatment. U.S. Medical Costs and Values 1995;1-24.

  23. Weir MR. Salt sensitivity: defining a major hypertensive subgroup. An interview with Matthew R. Weir, MD. Cardiovascular Horizons 1995; 9-12.

  24. Hanes DS, Weir MR. The failing heart and diuretic resistance: adaptation or altruism? Congestive Heart Failure Jan/Feb 1996; 11-16

  25. Weir MR. Antihypertensive combination therapy. Drugs of Today 1998; 34:5-9.

  26. Weir MR. The effect of dietary salt consumption on blood pressure and cardiovascular risk. Current Practice of Medicine. 1999; 6(2):125-127.

  27. Weir MR, Froch L. Weighing the renal effects of NSAIDS and COX-2 inhibitors. Clinical Dilemmas 2000;1:(2):3-15.

  28. Weir MR. Do living unrelated transplant recipients require anti-CD25 receptor antibody induction? Clinical Challenges in Transplant Medicine February 2002; 3(2): 7-8.

  29. Weir MR. Assessing risk and treating comorbid renal disease. Johns Hopkins University School of Medicine Advanced Studies in Medicine. Vol 5 (10C) – November 2005; S994-S1002.

  30. Weir MR. Hypertension and Cardiovascular Risk. US Cardiovascular Disease 2007 (2): 64-66.

  31. Weir MR. The Obesity Paradox: Impact of Obesity on the Prevalence and Prognosis of Cardiovascular Diseases. Practice Pearl. January 2009;121(1): 164-165.

  32. Weir MR. Leadership message: government and corporate responsibility to work with academia about the obesity epidemic. J Clin Hypertens (Greenwich). 2011 March;13(3):217-8.

  33. Weir MR. The author replies. Kidney Int. 2011 June;79(12):1379-80.

  34. Gradman A, Nesbitt S, Weir MR. Treating Special Populations with Hypertension: Is a Two-Drug or Fixed-Dose Combination Therapy Appropriate Initial Treatment in Hypertension? Med Roundtable Cardiovasc Ed. 2011;2(4):225–234


BOOK CHAPTERS


  1. Weir MR, Hise MK. Hypertensive renal damage. In: Saunders E, Brest AN eds. Cardiovascular Diseases in Blacks; Cardiovascular Clinics, F.A. Davis Company, Philadelphia, PA 1991; 21:115-132.

  2. Weir MR, Wolfsthal SD. Hypertension and the kidney. In: Boone JL, ed. Primary Care; Clinics in Office Practice. W.B. Saunders Company, Philadelphia, PA, 1991; 18:525-544.

  3. Weir MR. Clinical benefits of calcium antagonists in renal transplant recipients. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Hanley & Belfus, Inc. Philadelphia, PA, 1992;391-412.

  4. Weir MR. Calcium channel blockers. In: Vidt DG, Izzo JL, Black HR, eds. Hypertension Primer. The American Heart Association Press, Dallas, Tx, 1993; 311-313.

  5. Weir MR. Antihypertensive therapy: progression of renal injury. In: Hollenberg NK, ed. Hypertension: Mechanisms and Therapy. Atlas of Heart Diseases. Current Medicine, Philadelphia, PA, 1994; 10:1-18.

  6. Weir MR, Zachariah PK. Verapamil. In: Messerli FH, ed. Cardiovascular Drug Therapy. W. B. Saunders Co, Philadelphia, PA, 1996; 915-925.

  7. Weir MR, Bolli P, Prichard BNC, Weber MA. Bisoprolol. In: Messerli FH, ed. Cardiovascular Drug Therapy. W.B. Saunders Co, Philadelphia, PA, 1996; 557-568.

  8. Weir MR, Weber, MA. Quinapril hydrochloride. In: Messerli FH, ed. Cardiovascular Drug Therapy, W.B. Saunders Co., Philadelphia, PA, 1996; 794-801.

  9. Weir MR, Bakris GL, Toto RD, Flack JM, Williams B, Neutel JM. Hypertension. In: Gonick H, ed. Current Nephrology, Vol.19. Mosby-Yearbook, Chicago, IL, 1996; 203-241.

  10. Weir MR, Bakris GL, Toto RD, Flack JM, Bravo EI. Hypertension. In: Gonick H, ed. Current Nephrology, Vol.20. Mosby-Year Book, Inc., Chicago, IL, 1997; 209-241.

  11. Flack JM, Weir MR. Calcium antagonists as antihypertensive agents. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine, 2nd ed. Hanley & Belfus, Inc., Philadelphia, PA, 1998; 291-305.

  12. Weir MR. The clinical utility of calcium antagonists in renal transplant recipients. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine, 2nd ed. Hanley & Belfus, Inc., Philadelphia, PA, 1998:467-491.

  13. Weir MR. Antihypertensive therapy: progression of renal injury. In: Braunwald E, Hollenberg NK, eds. Atlas of Heart Diseases. Hypertension: Mechanisms and Therapy, 2nd ed, Vol.1. Current Medicine, Inc., Philadelphia, PA, 1998; 10:10.1-10.24.

  14. Cohen DJ, Weir MR. Post-transplant in-hospital care. In: Norman DJ, Suki WN, eds. Primer on Transplantation. American Society of Transplant Physicians, Thorofare, NJ, 1998;28:223-228.

  15. Ramos E, Weir MR, Klassen DK, Keay S. Donor and Recipient Evaluation. In: Malluche HH, ed. Clinical Nephrology, Dialysis, and Transplantation. Dustri-Verlag, Elmont, NY 1998.

  16. Weir MR. Dihydropyridine Calcium Antagonists. In: Izzo and Black, ed. Clinical Management: Sheps SG, Sica DA,Vidt DG. Hypertension Primer. American Heart Association, Second Edition. Baltimore, MD 1998.

  17. Weir MR. A patient with non-diabetic renal disease and proteinuria. In: P. Sleight, ed. Clinical cases in hypertension: Specific treatment strategies. 1998.

  18. Weir MR. Epidemiology and pathophysiology of hypertension. In: J. Neutel, ed. Cases 11,12,13,14. Cardiology - Pearls and Pitfalls Volume 1, 2, 3; 1998.

  19. Weir MR. Initial Choices in the Treatment of Hypertension. In: Oparil and Weber, eds. Hypertension: a companion to Brenner and Rector’s The Kidney. W.B.Saunders Company, 1999.

  20. Ramos ER, Weir MR, Klassen DK, Keay S. Donor and Recipient Transplantation Evaluation. In: Malluche HH, ed. Clinical Nephrology, Dialysis and Transplantation Dustri-Verlag, Elmont, NY 1999.

  21. Weir MR. Physiology of the Transplanted Kidney. In: Norman DJ, Suki WN, eds. Primer on Transplantation. American Society of Transplant Physicians, Thorofare, NJ, 2000

  22. Sowers JR, Neutel JM, Weir MR. Diuretics in Hypertensive Therapy. In: Hypertension Medicine. ed. Weber MA. Humana Press, Totowa, NJ 2000; 285-288.

  23. Weir MR. Choosing the First Agent. In: Hypertension Medicine. ed. Weber MA. Humana Press, Totowa, NJ 2000; 209-221.

  24. Dworkin LD, Weir MR. Hypertension in renal parenchymal disease: role in progression. In: Mechanism and Clinical Management of CRF. El Nahas AM, Harris KPG, Anderson S, editors. 2nd Edition, Oxford Unviversity Press, Inc. New York, 2000.

  1. Immunosuppression. In: Clinical Management of the Transplant Patient. Ed. Kuo PC, Schroeder RA, Johnson LB. Oxford University Press, New York, NY 2001; 27-50.

  2. Weir MR. Antihypertensive Therapy: Progression of Renal Injury. In: Atlas of Hypertension. 4th ed. ed. Hollenberg NK. Philadelphia: Current Medicine, Inc., 2003; 209-240.

  3. Ramos ER, Drachenburg CB, Portocarrero M, Wali RK, Klassen DK, Fink JC, Farney A, Hirsch H, Papadimitriou JC, Cangro CB, Weir MR, Bartlett ST. BK Virus Nephropathy Diagnosis and Treatment: Experience at the University of Maryland Renal Transplant Program. In: Clinical Transplants eds: Cecka and Terasaki. UCLA Immunogenetics Center, Los Angeles 2002.

  4. Ramos E, Drachenberg CB, Portocarrero M, Wali R, Klassen DK, Fink JC, Farney A, Hirsch H, Papadimitriou JC, Cangro CB, Weir MR, Bartlett ST. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland renal transplant program. In: Clinical Transplants. Cecka JM, Terasaki PI, eds. UCLA Immunogenetics Center 2003; 143-153.

  5. Klassen DK, Weir MR. Renal Transplantation. In: Scientific American Medicine 2003 Ed. Dale and Federman, eds. Web MD Inc, New York 2003; 2000-2010.

  6. Weir MR, Izzo JL Jr. Calcium Antagonists. In. Hypertension Primer 3rd Ed. Izzo and Black, Eds. Lippincott Williams & Wilkens: Philadelphia 2003; 433-437.

  7. Weir MR, Cangro CB, Klassen DK, Preparing Dialysis Patients for Renal Transplantation. In. Principles and Practice of Dialysis 3rd Ed. Henrich, Ed. Lippincott Williams & Wilkens: Philadelphia 2004; 648-661.

  8. Weir MR, Hanes D, Klassen DK. Antihypertensive Drugs. In: Brenner and Rector’s The Kidney. 7th ed. Brenner BM, Ed. Saunders, Philadelphia 2004; 2381-2453.

  9. Weir MR. ACE inhibitors and angiotensin receptor blockers in kidney disease: are we denying protection to patients? In: The Kidney and Hypertension. Bakris GL, Ed. Martin Dunitz: London and New York, 2004; 105-116.

  10. Weir, MR. Future developments in antihypertensive therapy. In: The Year in Hypertension, 2004. Gavras H, Ed. Clinical Publishing: Oxford, 2004; 257-263.

  11. Klassen DK, Weir, MR. 11 Renal Transplantation. 10 Nephrology. ACP Medicine Online. Dale DC, Federman DD, Eds. Web MD Inc., New York, 2004.

  12. Halloran, PF, Gourishankar, S, Vongwiwatana A, Weir, MR: Approaching the Renal Transplant with Deteriorating Function: Progressive Loss of Renal Function is Not Inevitable. In: Medical Management of Kidney Transplantation. Pages 389-402. Weir, MR, editor. Lippincott Williams & Wilkins Philadelphia, PA, 2005.

  13. Lakkis, J, Weir, MR, Danovitch GM. Waiting List Management. In: Medical Management of Kidney Transplantation, Pages 46-52. Weir, MR, editor. Lippincott, Williams & Wilkins Philadelphia, PA, 2005.

  14. Weir, MR. Prevention, Detection, and Clinical Presentations of Hypertension. Pages 1-12. Weir, MR, editor. Hypertension. American College of Physicians. Philadelphia, PA, 2005.

  15. Hanes DS, Weir MR: Initial Evaluation and Follow Up. Hypertension. A Companion to Brenner and Rector’s: The Kidney. Pages 543-554. Oparil S and Weber MA, editors. Elsevier Saunders. Philadelphia, PA, 2005.

  16. Lakkis J, Weir MR: Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. Hypertension. A Companion to Brenner and Rector’s: The Kidney. Pages 543-554. Oparil S and Weber MA, editors. Elsevier Saunders. Philadelphia, PA, 2005.

  17. Weir MR: Antihypertensive Therapy: Progression of Renal Injury. Atlas of Hypertension. Pages 221-254. N Hollenberg and E Braunwald, editors. Current Medicine LLC. Philadelphia, PA, 2005.

  18. Hanes DH, Weir MR: Calcium Agonists. Hypertension. Principles and Practice. Pages 517-530. Battegay EJ, Lip GYH, Bakris GL, editors. Taylor & Francis group. NW, D.C. 2005.

  19. Klassen DK, Weir MR: Renal Transplantation. ACP Medicine. Volume 2. 2006 Edition. A Publication of the American College of Physicians. Pages 2103-2114. Dale DC, Federman DD editors. WebMD Inc. New York, NY, 2006.

  20. Briglia AE, Weir MR: Can aggressive control of blood pressure prevent progression of kidney disease? Therapeutic Strategies in Hypertension. Pages 125-139. Clinical Publishing. Oxford, 2006.

  21. Salzberg DJ, Weir MR. COX-2 Inhibitors and Cardiovascular Risk. Inflammation in the Pathogenesis of Chronic Diseases: The COX-2 Controversy, Subcellular Biochemistry, R. E. Harris (ed) Volume 42, pages159-174.Springer 2007.

  22. Weir MR. Calcium Antagonists. Hypertension Primer 2008; 4 (C138): 465-469

  23. Weir MR. Efficacy and safety of RAS inhibition in diabetic patients with nephropathy. Renin Angiotensin System in Cardiovascular Medicine. 2007; Vol 3(3): 2-4.

  24. Weir MR, Hanes D, Klassen DK. Antihypertensive Drugs. Brenner & Rector’s The Kidney. Phildelphia:Saunder Elsevier, 2008:1596-1645.

  25. Salzberg DJ, Weir MR. Recent transplant issues in hypertension. Ed Raymond Townsend, The Year in Hypertension. 2008:7:227-242.

  26. Weir MR, Brown EM. What is the optimal treatment in obesity-related hypertension. In: Weir, MR. Evidence-based Management of Hypertension. Tfm Pub Ltd, Castle Hill Barns, Harley, Nr Shrewsbury, UK, 2010. 29-40.

  27. Hanes DS, Narakala NK, Weir MR. How Low Should Systolic and Diastolic Blood Pressure Be? In: Clinical Challenges, Hypertension II, ed Toth and Sica. 2010; 51-64.

  28. Weir MR, Hanes D, Klassen DK. Antihypertensive Drugs. In: Brenner and Rector’s The Kidney. 9th ed. Brenner BM, Ed. Saunders, Philadelphia 2012; 1824-1867: chap 49.

  29. Brown EM, Salzberg DJ, and Weir MR. Renal Consequences of Prostaglandin Inhibition in Heart Failure. In: The Kidney in Heart Failure. George L. Bakris, Editor. Springer. 2012; 117-126

  30. Weir MR and Mavanur M. The Use of Angiotensin-Converting Enzyme Inhibitors in the Renal Transplant Recipient. In:ACE Inhibitors Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics 2014;Vol 2:191-202.

  31. Karadsheh FF and Weir MR. Hematologic Complications of Chronic Kidney Disease: Leukocyte and Monocyte Function. In: Chronic Renal Disease. Kimmel, PL. and Rosen

  32. Weir MR. ACE inhibitors and angiotensin receptor blockers in kidney disease: are we denying protection to patients? In: The Kidney and Hypertension. Bakris GL, Ed. Martin Dunitz: London and New York, 2004; 105-116.



1   2   3   4   5   6   7


The database is protected by copyright ©dentisty.org 2016
send message

    Main page